Cancer News

Managing Side Effects From EGFR Inhibitors (04/10/2018)

CancerConnect News: Epidermal Growth Factor Receptor (EGFR) inhibitor drugs are a type of precision cancer medicine commonly used to treat lung, colon, head and neck and other cancers that over express the EGFR.  There are several EGFR inhibitor drugs and these cause similar side effects. The EGFR pathway is a normal biologic pathway found in …

Continue reading "Managing Side Effects From EGFR Inhibitors"

Targeting both BRAF and EGFR doubles progression-free survival in metastatic colorectal cancer (10/16/2017)

Recent successes in genetically targeted precision cancer medicines are improving outcomes in a number of cancers.  Ensuring patients undergo genomic sequencing to determine if they have treatable targets is increasingly important to ensure patients receive the most appropriate personalized care. Precision cancer medicine utilizes molecular diagnostic testing, including DNA sequencing, to identify cancer-driving abnormalities in …

Continue reading "Targeting both BRAF and EGFR doubles progression-free survival in metastatic colorectal cancer"

NSAIDs Decrease Risk of Colorectal Cancer (09/18/2017)

Nonsteroidal anti-inflammatory drugs (NSAIDS) are medicines that are used for the treatment of a wide range of musculoskeletal illnesses including spinal disorders, osteoarthritis and inflammatory conditions like rheumatoid arthritis. NSAIDs effectively relieve pain, inflammation, and fever.  A number of treatment guidelines for osteoarthritis, rheumatoid arthritis, and chronic low back pain recommend the use of NSAIDs …

Continue reading "NSAIDs Decrease Risk of Colorectal Cancer"

Proton Beam Therapy may Improve Outcomes for Rectal Cancer (03/06/2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum, pancreatic, or small intestine. This treatment approach is often associated with improved outcomes but the radiation may also cause …

Continue reading "Proton Beam Therapy may Improve Outcomes for Rectal Cancer"

Addition of Eloxatin® Following Surgery Delays Cancer Progression in Certain Colorectal Cancers (07/28/2016)

The addition of the chemotherapy combination consisting of Eloxatin (oxalipatin) plus 5-fluorouracil (5 FU) following surgery reduces the risk of cancer progression among patients with deficient mismatch repair (dMMR) stage III colorectal cancer. These results were recently published in the Journal of the National Cancer Institute. Among patients with colorectal cancer that has spread to … Continue reading "Addition of Eloxatin® Following Surgery Delays Cancer Progression in Certain Colorectal Cancers"

Herceptin® Plus Tykerb® Promising for HER2-Positive Colorectal Cancer (05/11/2016)

The treatment combination consisting of Herceptin (trastuzumab) plus Tykerb (lapatinib) provides significant anti-cancer activity in colorectal cancer that overexpresses the human epidermal growth factor receptor 2 (HER2). These results were recently published in The Lancet Oncology. The HER2 receptor is a protein that is normally found on the surface of several different types of cells … Continue reading "Herceptin® Plus Tykerb® Promising for HER2-Positive Colorectal Cancer"

Another Study Confirms That Daily Aspirin Lowers Risk of Colorectal & Other GI Tract Cancers (05/09/2016)

The regular use of aspirin significantly reduces the overall risk of cancer, especially colorectal and other gastrointestinal tract cancers, according to a study published in JAMA Oncology.1 The recent report supports the results of previous clinical studies that have also demonstrated that the daily use of aspirin reduces the risk of death from several common cancers, including lung, … Continue reading "Another Study Confirms That Daily Aspirin Lowers Risk of Colorectal & Other GI Tract Cancers"

EPI proColon® – Novel Blood Screening Test Approved for Colorectal Cancer Detection (05/02/2016)

The United States Food and Drug Administration (FDA) has approved Epi proColon®, a test that screens for colorectal cancer from a simple blood draw. The approval specifies that EPI proColon is only indicated for individuals at an average risk of developing colorectal cancer who choose not to undergo other colorectal cancer screening methods specified in … Continue reading "EPI proColon® – Novel Blood Screening Test Approved for Colorectal Cancer Detection"

Anesthesia Increases Colonoscopy Risks (03/04/2016)

Though colonoscopy is often performed with anesthesia, a recent study published in the journal Gastroenterology has found that sedation increases the risk of complications.1 A colonoscopy is a type of exam that a doctor uses to check the lining of the large intestine (colon) for signs of cancer, abnormal areas that could turn into cancer, … Continue reading "Anesthesia Increases Colonoscopy Risks"

Vistogard® Approved for Life-Threatening Toxicities of Certain Chemotherapy Agents (02/11/2016)

The United States Food and Drug Administration (FDA) approved Vistogard (uridine triacetate) for the treatment of life-threatening toxicities caused by the chemotherapy drugs fluorouracil or capecitabine. The approved indication is for the “emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil or Xeloda (capecitabine), or who develop certain severe … Continue reading "Vistogard® Approved for Life-Threatening Toxicities of Certain Chemotherapy Agents"